Related Experiment Video
Updated: Jun 15, 2025

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
Nurture growth: Ketogenic diet therapy and growth velocity in infants under 12 months with epilepsy - A systematic
Anika Maass1, Francesca Sutter2, Petra Trimmel-Schwahofer2
1Children's Hospital AUF DER BULT, Hannover, Germany.
Insights
Ketogenic diet therapy (KDT) does not impede growth in infants during the first year of life when monitored. However, growth velocity may decrease in the second year of KDT treatment.
Area of Science:
- Pediatric Neurology
- Nutritional Science
- Epileptology
Background:
- Ketogenic diet therapy (KDT) is an established treatment for early infantile epilepsy.
- The effect of KDT on infant growth remains a subject of debate.
- Previous studies have yielded conflicting results regarding growth parameters during KDT.
Purpose of the Study:
- To evaluate the impact of early Ketogenic Diet Therapy (KDT) on growth velocity and height percentiles in infants.
- To systematically review existing literature on KDT and infant growth.
- To analyze data from a prospective cohort of infants treated with KDT.
Main Methods:
- Systematic literature review of studies on infant growth (<12 months) under KDT.
- Analysis of a prospective database of 63 infants (<12 months) receiving KDT.
- Assessment of growth velocity z-scores, height/weight SD, BMI, and macronutrient intake.
Main Results:
- Literature review (7 studies) showed varied growth outcomes; growth velocity data was limited.
- In the prospective cohort, median growth velocity z-score was 1.03 in the first year.
- No decrease in growth velocity or height percentiles was observed up to one year of age with KDT.
Conclusions:
- KDT, with adequate nutritional monitoring, does not negatively impact infant growth in the first year.
- Growth velocity may decline in the second year of KDT treatment.
- Early epilepsy onset and earlier KDT initiation correlated with slower first-year growth velocities.
Abstract:
Ketogenic diet therapy (KDT) is well established for the treatment of early epileptic encephalopathies and specific aetiologies; however, the impact on growth in infancy remains controversial. Our aim was to examine the influence of early KDT on growth velocity and height percentiles completing two tasks. First, we systematically reviewed the literature on growth in infants younger than 12 months. Second, we analysed data from our prospective database, including infants <12 months (n = 63) treated with KDT. The literature review (n = 7) remains descriptive and includes growth percentiles and z-scores as growth velocity was not described. Studies up to 2010 used fasting, calorie restrictions, and ratios >3:1. In individual cases, significant growth delays were found; other authors did not find any changes in growth parameters. Study endpoints in our own cohort included z-scores of growth velocity, standard deviation (SD) of height, weight, BMI, deviation from individual height percentile, and daily macronutrient intake. The median z-score of growth velocity was 1.03 (first year of life). After three months, median daily intake of protein and energy was 1.68 g/kg and 85 kcal/kg. Until the age of one year, neither growth velocity nor individual growth percentiles decreased. Infants showed distinct growth improvements at three months, likely due to continuous nutritional monitoring and reduction in seizures. In the second year of life, z-scores of growth velocity decreased in patients still receiving KDT (from 1.03 at 12 months to -1.5 at 24 months). Furthermore, younger age at epilepsy onset and at KDT start correlated with slower growth velocities in the first year of life. With appropriate nutritional intake and monitoring, KDT does not reduce growth in the first year of life. Future directions might be to study the impact of KDT on growth velocity and growth hormones throughout childhood.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Related Concept Videos
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Electroconvulsive Therapy
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...